Endomag is thrilled to announce it has successfully raised 310,000,000 in funding, marking a significant milestone in its journey to revolutionize cancer care globally. Since its inception in 2007 as a spin-out from the University of Houston and University College London, Endomag has remained steadfast in its mission to improve the global standard of cancer treatment. The new capital will empower the company to accelerate the development and commercialization of its innovative clinical platform, which includes the Sentimag® probe, Magseed® marker, and Magtrace® lymphatic mapping agent. These groundbreaking technologies are already being utilized by leading physicians and cancer centres across the world to provide more precise and less invasive care for breast cancer patients.
The funding will be strategically deployed to enhance research and development efforts, scale up manufacturing capabilities, and expand international market reach. By doing so, Endomag aims to help women with breast cancer avoid unnecessary surgery when it isn’t needed and ensure improved outcomes when surgical intervention is required. This financial milestone not only reaffirms investor confidence in Endomag’s cutting-edge approach but also underscores the company’s commitment to transforming the treatment landscape in oncology. With tens of thousands of women already benefiting from its technologies, Endomag is poised to extend its impact further, refining surgical techniques and advancing diagnostic accuracy in the fight against cancer. Operating from its headquarters in Cambridge, United Kingdom, Endomag continues to embody innovation, clinical excellence, and a passionate pursuit of better outcomes for patients around the globe.
